Identifying genes that modify symptoms of Alzheimer's disease (AD) will provide novel therapeutic strategies to prevent, cure or delay AD. To discover genetic modifiers of AD, we combined a mouse model of AD with a genetically diverse reference panel to generate F1 mice harboring identical 'high-risk' human AD mutations but which differ across the remainder of their genome. We first show that genetic variation profoundly modifies the impact of causal human AD mutations and validate this panel as an AD model by demonstrating a high degree of phenotypic, transcriptomic, and genetic overlap with human AD. Genetic mapping was used to identify candidate modifiers of cognitive deficits and amyloid pathology, and viral-mediated knockdown was used to functionally validate Trpc3 as a modifier of AD. Overall, work here introduces a 'humanized' mouse population as an innovative and reproducible resource for the study of AD and identifies Trpc3 as a novel therapeutic target.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by both dementia and the accumulation of neuropathological amyloid plaques and tau tangles (Selkoe, 1991) . Mutations that drive overproduction of betaamyloid (Aβ) have been shown to cause early onset familial AD (FAD), leading to a model in which production and accumulation of Aβ is thought to be an initiating event in a sequence leading to memory loss, neurodegeneration, gliosis, and synaptic dysfunction (Hardy and Higgins, 1992) . However, strategies to directly target amyloid for clearance have not translated into successful treatments and the number of deaths attributable to AD as well as costs associated with the disease continue to rise. In addition, even among patients with FAD mutations, the age at first symptom onset is widely variable, with some patients exhibiting symptoms decades later than predicted based on mutation status, suggesting additional genetic factors exist that may provide protection from disease (Ryman et al., 2014) .
Although age is the greatest risk factor for developing AD, it is increasingly clear that genetics and family history play a large role. The heritability of AD is estimated to be in the range of 50-80%, indicating an individual's susceptibility or resilience to disease is, at least in part, determined by genetic makeup (Gatz et al., 1997) . Indeed, a number of genetic risk factors have been identified in recent years (Lambert et al., 2013) . However, besides APOE and TREM2, effect sizes of common variants are generally small and a large proportion of the heritability remains unexplained by currently identified variants (Ridge et al., 2013) . In addition, the study design utilized in most genome wide association tests (e.g. case-control) is primed to identify variants associated with risk of AD, rather than variants that modify an individual's disease trajectory and/or delay the onset of disease and provide protection from AD. This is due primarily to the fact that asymptomatic individuals rarely enter the clinic for treatment, and even if they are included in a study, are likely to be enrolled as cognitively normal controls.
Identifying genetic variants and pathways involved in protection from AD will provide valuable targets for new therapeutics to prevent or delay the onset of symptoms. Individuals with high-risk genotypes but who fail to present with clinical symptoms of AD represent an ideal population in which to study resilience. However, causal mutations in APP and PSEN1/2 (i.e. high-risk genotypes) are rare in humans, greatly limiting statistical power and opportunity for observation. In addition, access to brain tissue at early disease time points, before overt symptom onset, is limited for obvious reasons in human studies, precluding the identification of causal molecular mechanisms. Thus, mouse models harboring causal AD mutations are an important tool that present many advantages including defined high-risk genotypes, early access to brain tissue, and precise environmental control.
Recent arguments concerning the use of mouse models point to a lack of predictive validity and failure to translate into successful treatments (Onos et al., 2016) . However, there are a variety of potential explanations for this disconnect between AD in mice and humans, including the fact that most mouse models of AD are maintained on only a single or a few genetic backgrounds. This includes backgrounds of mixed origins (Onos et al., 2016) , which may confound interpretation of results. Previous studies have attempted to identify genes involved in the modification of AD symptoms in mice from mapping studies in F2 populations (Ryman et al., 2008; Sebastiani et al., 2006) . However, these studies and individual strain-by-strain comparisons (Jackson et al., 2015; Sipe et al., 1993) have generally suffered from poor mapping resolution and/or an inability to pinpoint causative genes.
In order to identify specific genes involved in modifying resilience to AD symptoms in a more robust way, we developed the first AD transgenic mouse genetic reference panel. This panel, which we term the AD-BXDs, combines two well established resources: 1) the 5XFAD transgenic line that recapitulates various aspects of the human disease, including amyloid-β42 accumulation, cognitive deficits, and neuron loss , and 2) the BXD genetic reference panel, the largest and best-characterized series of recombinant inbred strains derived from the two common inbred strains C57BL6/J (B6) and DBA2/J (D2) . The BXD panel segregates more than 4.8 million sequence variants, including many in genes known to confer risk for AD (Table S1 ). This AD-BXD panel of F1 mice provides an ideal opportunity to monitor the phenotypic outcome of individuals harboring identical high-risk FAD mutations in human APP and PSEN1 genes, raised in identical environments, but whose allelic contributions differ across the remainder of the genome. This approach parallels and complements searches for modifier genes that have been conducted in human patients, particularly modifiers of monogenic diseases caused by highly penetrant alleles similar to the 5XFAD transgene [i.e. the CFTR gene known to cause cystic fibrosis (Corvol et al., 2015) ]. Overall, results presented here demonstrate the utility of the AD-BXD reference panel as a resource for the study of AD genetics and will likely provide critical insight into disease mechanisms.
Results

Genetic background modifies expressivity of FAD mutations
In order to evaluate the impact that genetic background has on the expressivity of human causal FAD mutations on behavioral and molecular phenotypes, we generated a panel of 26 genetically diverse F1 mouse strains with and without FAD mutations. Female B6 mice heterozygous for the dominant 5XFAD transgene were crossed to males from the BXD genetic reference panel to generate F1 progeny carrying the 5XFAD transgene (AD-BXDs, or carriers) or non-transgenic littermates (Ntg-BXDs, or non-carriers; Figure 1A ). Working memory and body weight was monitored bi-monthly, and more in-depth phenotyping that included tests of motor function and anxiety was performed at both 6 and 14 months of age ( Figure 1B) . A subset of mice were subsequently tested for long-term spatial learning and memory function using a contextual fear conditioning (CFC) paradigm. This subset was immediately harvested following CFC testing, and tissue was collected for biobanking and later use, including RNAsequencing and ELISAs as described below.
As expected, the 5XFAD transgene accelerated the age at onset (AAO) of working memory deficits in carriers relative to non-carriers ( Figure 1C) , and exacerbated CFC learning and memory deficits, particularly by 14 months (Figure 1D-E) . In addition, the effect of the 5XFAD transgene significantly altered the expression of genes known to be misregulated in AD, particularly Bin1, Cd33, Clu (Karch et al., 2012) , Trem2 (Piccio et al., 2016) , and C1qa (Hong et al., 2016) , Figure 1F . However, the impact of causal FAD mutations on cognitive performance and risk gene expression varied widely depending on the specific background strain evaluated. In particular, the observed variation in AAO mirrors the variation in human patients reported by Ryman and colleagues (2014) , suggesting our panel captures a portion of the phenotypic heterogeneity observed in human FAD patients. Heritability estimates comparing between-strain variance due to genetic diversity to total sample variance suggest there is a significant genetic component underlying observed variation, particularly on cognitive traits (Table 1) . These results were not explained by an effect of strain, age, or sex on the transcription of the 5XFAD transgene itself as measured by alignment of RNA-sequencing reads to the mutated human APP or PSEN1 sequence (Figure 1H-K) . This suggests naturally occurring variants that segregate across the ADBXDs play a significant role in determining susceptibility and/or resilience to changes in cognitive function and gene expression caused by high-risk FAD mutations.
AD-BXD transcriptome shows high concordance with sporadic late-onset AD signature
To evaluate the translational validity of incorporating naturally occurring genetic variation in AD models, we compared the expression of a set of 60 core genes previously defined as a human AD consensus signature (Hargis and Blalock, 2017 ) across a subset of AD-BXD and Ntg-BXD strains using RNA-sequencing of hippocampal tissue (Table   S2) . We observed high concordance between our mouse panel and human AD signatures -83% (50 of 60) of genes in the human AD signature had fold changes in the same direction in our AD-BXD panel relative to Ntg-BXDs ( Figure 1G ).
This effect replicated in 3 independent human datasets tested ( Figure S1 ). Beyond this core set of 60 genes, our AD-BXD panel also displayed similarities to human AD in terms of functional enrichment of all significantly upregulated and downregulated genes (see Hargis and Blalock 2017 and Table S3 ). Pathways common to genes downregulated in human AD and the AD-BXDs include pathways related to the synapse (GABAergic, glutamatergic, and cholinergic synapse in mouse vs synapse part and synaptic vesicle in human). Pathways common to genes upregulated in both populations include cell adhesion (cell adhesion molecules in the mouse vs cell adhesion in human) and cell death (apoptosis in mouse vs cell death in human) (Hargis and Blalock, 2017) . Overall, the incorporation of genetic diversity into a mouse model of AD resulted in a transcriptome profile that more closely matched human AD than previous AD models with limited genetic background variation as described by Hargis and Blalock (2017) .
Identification of genetic correlates of age at first symptom onset in the AD-BXD panel
To identify candidate mechanisms that influence susceptibility or resilience to FAD mutations, we sought to identify naturally occurring variants in the AD-BXDs specifically responsible for the observed heritable variation in AAO (Fig 1C) . In order to define AAO, we used the Y-maze test of spontaneous alternation to longitudinally assess working memory in AD-BXD and Ntg-BXD mice. An animal was classified as impaired when performance dropped below chance levels (50%, indicating no memory for which arm of the maze was most recently visited) and the age at which impairment was first observed was termed the animal's AAO. The average AAO for each AD-BXD strain varied widely [ Figure 2A , n = 210 mice (109 female/101 male) across 26 strains -effect of strain, F(25,209) = 3.0, p = 0.04; no main effect of sex, p > 0.1], with susceptible strains exhibiting an AAO as early as 4 months and resilient strains maintaining cognitive function to the latest time point tested ( Figure 2B) . Notably, variation in AAO was not explained by differences in locomotor function or exploratory behavior ( Figure S2 ).
We first performed genetic mapping using r/qtl in an attempt to identify specific loci (i.e. quantitative trait loci, QTLs) that are that are critical for modifying the AAO across the AD-BXDs. However, no significant QTL was identified for AAO ( Figure 2C) , and genotype at the peak marker on chromosome 4 explained only 12% of the variance. This result suggests multiple loci with relatively small effect sizes may regulate AAO. Consistent with this, we identified a relationship between AAO and the hippocampal expression of known modifiers of human FAD [ Figure 2D , Snx25 , Prnp (Dermaut et al., 2003), Inpp5d, Clu, and Picalm (Lambert et al., 2013) in red].
In addition, we identified twelve novel genes as associated with AAO after stringent Bonferroni correction for multiple comparisons (n = 21,215 genes, Figure 2D in black). As deficits in working memory performance in AD mouse models most closely parallels the earliest AD-related cognitive deficits detected in humans during the late preclinical phase of the disease (Webster et al., 2014) , these gene candidates represent new targets to delay the onset of disease.
Apoe modifies contextual fear learning deficits in AD-BXDs
Next, we sought to identify specific factors responsible for the observed variation in CFC acquisition in the ADBXDs (Fig 1D) . During CFC acquisition, a mouse that begins to associate the training context with the impending shock will exhibit increasing levels of freezing, a species-specific defensive response thought to indicate fear (Fanselow, 1984) .
The slope of the change in average freezing across the 4 post-shock intervals was used to derive an acquisition curve for each strain. Although the 5XFAD population was impaired relative to non-carrier littermates ( Figure 1D Genetic mapping was performed using strain averages at both 6 and 14m, with age and sex included as covariates in a single QTL model. A significant QTL explaining 21% of the phenotypic variance was detected on chromosome 7 (1.5 LOD confidence interval = 15.90-20.38 Mb, LOD = 7.1, Figure 3C ). AD-BXD strains harboring a D allele at this peak marker showed lower levels of acquisition [t(1, 80) = 4.6, p < 0.001, Figure 3D ]. However, this effect was not observed when the peak marker was tested for association with acquisition in the Ntg-BXD population [t(1,75) = 1.4, p = 0.15, Figure 3E ], demonstrating the effect of the identified QTL is specific to the AD-BXD population. This interval is syntenic to human 19q13.3 and contains approximately 100 genes with human orthologs and that contain either single nucleotide polymorphisms (SNPs), insertions/deletions (indels), or structural variants across our panel as annotated by the Sanger Mouse Genomes Project (Keane et al., 2011) -representing viable positional candidates that may contribute to observed variation in CFC acquisition. This included multiple genes previously shown to modify human individuals' risk of AD, most notably Apoe, Tomm40, and Apoc1. All positional candidates with detectable levels of expression in the hippocampus (n = 70) were first filtered by correlation of hippocampal gene expression with CFC acquisition, as the hippocampus is critical for CFC (Holland and Bouton, 1999) . Remaining after this analysis were 15 genes that passed stringent Bonferroni correction for association with CFC learning (Table S4) . Of these genes, Apoe emerged as the candidate with strongest biological evidence for a causal involvement in phenotypic regulation. In addition to being the best-known risk factor for human AD, Apoe was the positional candidate most strongly related to genotype (log 2 FC Ntg-BXD vs AD-BXD = 0.8. adj. p = 7.1e-58) and age (log 2 FC 5XFAD adult vs 5XFAD aged = 0.4. adj. p = 6.8e-10) across our F1 population (Table S4) . AD-BXD lines harboring a copy of the D Apoe allele performed significantly worse on acquisition of CFC regardless of age [t(1,80) = 4.5, p < 0.001, Figure 3F ]. In addition, the correlation observed between Apoe expression and CFC acquisition (Table S4 ) appears to be driven by mice harboring the D allele, as expression was only significantly correlated with contextual fear acquisition when mice harbored the D allele (genotype BD, r = -0.7, p < 0.01; genotype BB, r = -0.3, p = 0.09; Figure 3G ). This suggests that while more Apoe is overall detrimental to learning, this effect is exacerbated when the D allele of Apoe is present. Similar allele-specific results have been observed when over-expressing human APOE in transgenic mice (Bien-Ly et al., 2012) . Interestingly, the D allele harbors only a single SNP when compared to the B6 allele, and this missense mutation causes the D2 sequence to match the human ε4 variant more closely than the B6 sequence ( Figure 3H ). As both alleles (ε4 and D) confer elevated risk for AD cognitive deficits, these results provide evidence that 1) the D allele of Apoe functionally recapitulates human APOEε4 (Liu et al., 2013) , and 2) shared genetic mechanisms confer susceptibility to AD in the AD-BXD and human populations. These results support the contention that discovery of novel genetic modifiers of AD symptoms using the AD-BXDs are likely to translate to humans.
Susceptibility to AD memory deficits is regulated by genetic variants on chromosome 2
We next assessed the impact of the AD transgene in our panel on long-term contextual fear memory (CFM) as described previously . AD-BXD mice exhibited impaired CFM by 14 months (Figure 1E ), and the extent of variation in CFM at both age points varied significantly by strain [n = 355 mice (212 female/143 male) across 28 strains and 2 ages -effect of strain, F(27,354) = 3.6, p < 0.001, Figure 4A -B; no main effect of sex (p = 0.4)]. Variation in CFM was not association with strain-specific variation in gross sensorimotor abilities, anxiety, or pain sensitivity as measured by post-shock reactivity ( Figure S4 ). Overall, results suggest variation in CFM is due primarily to straindependent differences in long-term memory and as a quantitative trait, is suitable for discovery of genomic loci associated with cognitive risk and resilience to AD mutations using QTL mapping.
QTL mapping was performed using strain averages at both 6 and 14 months, with age and sex included as covariates in a single QTL model. A significant QTL explaining 21% of the phenotypic variance was identified on chromosome 2 (1.5 LOD confidence interval = 23.55-27.03 Mb, LOD = 5.9 Figure 4C ). In the AD-BXD panel, D alleles at the peak marker in this QTL were associated with lower levels of freezing and poorer cognitive performance [t(1,80) = 4.5, p < 0.001, Figure 4D ). When tested for association with CFM in the Ntg-BXD panel, this marker also showed significant association with CFM [t(1,75) = 3.0, p = 0.004, Figure 4E ]. However, this marker explained much less of the heritable variation in CFM in the Ntg-BXD panel (only 11% compared to 21% in the AD-BXD panel), suggesting that while this QTL may have broad relevance to CFM abilities, the effect is much more pronounced in the presence of the 5XFAD transgene. The QTL interval contained 62 positional candidates with naturally occurring genetic variants across our panel, six of which had gene expression significantly correlated with the CFM trait after stringent Bonferroni correction for multiple comparisons ( Table S5 ). The expression of each these six candidates was mapped as separate quantitative traits in order to identify QTLs regulating observed variation in gene expression (expression QTL, or eQTL).
A significant eQTL was identified only for Dpp7 and overlapped the location of the gene itself [1.5 LOD confidence interval = 16.14 -23.75, LOD = 9.0], indicating the expression of Dpp7 is subject to local, or cis, regulation. As expected, genotype at the peak cis eQTL marker was significantly associated with gene expression, with one copy of the D allele associated with much higher levels of hippocampal Dpp7 expression [t(1, 46) = 5.4, p < 0.001, Figure 4F ]. As expected considering the association of D alleles with poorer cognitive performance, higher levels of hippocampal Dpp7 expression were significantly associated with poorer CFM (r = -0.47, p < 0.001, Figure 4G ). Taken together, these data suggest a role for Dpp7 as a negative regulator of CFM in the AD-BXD panel and a candidate modifier of susceptibility to AD.
AD-BXD panel exhibits heritable variation in amyloid pathology attributable to genetic variants on chromosome 3
In addition to deficits in cognitive function, one of the hallmarks of AD is accumulation of toxic Aβ1-42 (Aβ42), thought to be an initiating factor in a cascade of symptoms eventually leading to neuron loss and dementia (Hardy and Higgins, 1992) . To measure Aβ42 levels across the panel, brain extracts from 24 distinct AD-BXD lines were assayed in duplicate on Aβ42-specific sandwich ELISA (n = 154 mice (89 female, 65 male) across 23 strains and 2 ages, Figure 5A previous report using a single genetic background suggesting the 5XFAD model preferentially affect females (Sadleir et al., 2015) .
In order to identify genetic factors involved in regulating Aβ42, r/qtl was used to perform genetic mapping. While no significant QTLs were detected for Aβ42 load at 6 months ( Figure 5C ), a significant QTL on chromosome 3 explaining 15% of the phenotypic variance was detected for Aβ42 load at 14 months (1.5 LOD confidence interval = Chr 3: 36.08-45.08 Mb, LOD = 4.5, Figure 5D ). D alleles at the peak marker associated with higher Aβ42 levels across the panel ( Figure 5E ). Within this QTL, there were 22 positional candidates with sequence differences between B6 and D2, each of which represent viable positional candidates that may directly contribute to the variation in Aβ42 levels ( Table   S6) . No candidate exhibited significant correlation between hippocampal gene expression and amyloid levels, suggesting to us that the identified variant may exert its effect through alteration of protein function rather than transcript expression.
Of the 20 positional candidates, six candidates contained both SNPs and indels predicted to have a high functional impact on either transcript or protein structure according to Ensembl Variant Effect Predictor (McLaren et al., 2016) . Three of these six genes, fibroblast growth factor 2 (Fgf2) (Donnini et al., 2006; Katsouri et al., 2015) , cyclin A2 (Ccna2) (Chandrasekaran and Bonchev, 2016) , and interleukin 2 (Il2) (Alves et al., 2017) have previously been associated with Aβ levels, suggesting variants in one or multiple genes in this region may influence amyloid load. Of the remaining 3 genes that had not been previously implicated as involved in amyloid accumulation, Trpc3 emerged as the gene with the most biological evidence for a potential functional role in AD.
Targeted knockdown of positional candidate Trpc3 reduces Aβ42 load and AD-related cognitive symptoms
Trpc3 is a member of the transient receptor potential channel family and is permeable to cations including calcium (Dietrich et al., 2005) . Misregulation of calcium signaling has previously been implicated in the pathogenesis of AD (LaFerla, 2002) , and Trpc3 itself has recently been implicated in neuronal excitability and cognitive function in adult mice . In addition, Trpc3 function has been shown to be sensitive to cellular cholesterol (Graziani et al., 2006) , a pathway closely linked to AD by GWAS hits such as APOE, CLU, and ABCA7 (Karch and Goate, 2015) .
Across the AD-BXDs, Trpc3 contains both a sequence variant and an insertion in a predicted splice region, further strengthening a possible role for Trpc3 in in cognitive deficits and amyloid processing. Notably, the insertion occurs in exon 10 of Trpc3 (NM_019510), and a calmodulin/IP 3 R binding site within exons 9 and 10 has previously been shown to modulate TRPC3 activation (Zhang et al., 2001) . Given that antibodies directed against beta-amyloid have not resulted in disease-modifying treatments, and beta-amyloid does not correlate strongly with cognition in either humans or our AD-BXD panel (Figure S5 ), we hypothesized that targeting a putative modulator of amyloid pathology that also has cognitive function-enhancing capabilities (i.e. Trpc3) may provide an added benefit to susceptible strains by reducing pathology and increasing neuronal excitability.
Since TRPC3 protein is increased in hippocampus from 5XFAD mice compared to Ntg controls [ Figure 6A , n = 4/grp, t(1,6) = 3.7, p = 0.01], we injected our previously validated AAV9 viral vector containing either shRNA targeting
Trpc3 (shRNA-Trpc3) or a scrambled shRNA control (shRNA-Ctrl) directly in the dorsal hippocampus of presymptomatic male 4 month-old 5XFAD-B6SJL mice . This strain was chosen as it a susceptible strain with robust amyloid deposition when compared to mice from our AD-BXD panel ( Figure 5A ). The mice were aged to 9 months, a time point at which a majority of the population exhibits both amyloid accumulation and memory deficits (Kaczorowski et al., 2011; Oakley et al., 2006) , and then working memory and CFM was assessed shRNA-Trpc3 vs 5XFAD shRNA-Ctrl, p < 0.05 on both tasks] and were statistically indistinguishable from controls on the CFM task (post-hoc 5XFAD shRNA-Trpc3 vs Ntg shRNA-Ctrl p > 0.05). Importantly, no significant effects of group on total distance traveled or arms entered in the y-maze, or baseline freezing during CFC training, were observed indicating no difference between groups on measures of total activity or anxiety ( Figure S6 ). Similar effects were observed in non-transgenic mice, demonstrating a general effect of Trpc3 knockdown on cognitive aging ( Figure S7 ).
Finally, we investigated the effects of Trpc3 knockdown on accumulation of Aβ42. Mice were harvested at 10 months and one hemisphere of each brain region was fixed in 4% PFA. Immunohistochemistry for Aβ42 was performed and number of plaques counted using Image J's particle analysis software (Hurtado et al., 2010) . 5XFAD shRNA-Ctrl mice exhibited a robust increase in the total number of plaques observed in the cortex and hippocampus ( Figure 6E ). In contrast, 5XFAD mice treated with shRNA-Trpc3 showed a decrease in the number of plaques [effect of group: F(2,11) = 5.5, p = 0.03; post-hoc one-tailed t-test 5XFAD shRNA-Ctrl vs 5XFAD shRNA-Trpc3: t(1,7) = 2.0, p = 0.04] and were not significantly different than Ntg mice [post-hoc t-test 5XAFD shRNA-Trpc3 vs Ntg shRNA-Ctrl: t(1,6) = 1.8, p = 0.12]. These results demonstrate that in addition to a general role in cognitive aging, Trpc3 plays a disease-specific role in the regulation of amyloid levels in AD.
To assess the translational relevance of this finding, we next evaluated the relationship between TRPC3 and human AD. Using ROS/MAP data, a significant association was identified between TRPC3 expression in the prefrontal cortex of neuritic plaque positive AD cases and a brain-wide measure of amyloid burden (see Methods), even after adjusting for age at death and sex (p = 0.0005, Figure 6G ). As in our mouse panel, higher levels of TRPC3 were associated with an increased amyloid burden. In contrast, no association was observed between TRPC3 expression and neurofibrillary tangles, cerebral amyloid angiopathy, or Lewy bodies (p > 0.05). In addition, publically available data was mined for evidence of TRPC3 association with human AD. Of three SNPs annotated to TRPC3 in the International
Genomics of Alzheimer's Project (IGAP) dataset (Lambert et al., 2013) , one SNP displayed a nominal association with AD (rs114991240, uncorrected p = 0.03). Finally, TRPC3 appears in the same module as known AD risk genes APOE, CLU, and DSG2 in a gene regulatory network constructed from post-mortem brain tissue from LOAD patients and cognitively normal controls (Zhang et al., 2013) , suggesting its role in a larger regulatory network may influence risk of AD. Together, these results suggest that while variants in TRPC3 itself may not play a highly significant role in regulating risk of AD in human populations, mechanisms and pathways in which TRPC3 is involved (e.g. neuronal excitability, cholesterol metabolism, amyloid production and clearance) are important for modulating risk of AD. Overall, results here implicate Trpc3 for the first time in regulation of AD pathogenesis and demonstrate the ability to transition from candidate gene identified by QTL mapping to functional validation in an in vivo mouse model and translational evaluation using human datasets.
Discussion
Transgenic reference panel allows for new approach to study AD genetics
It has long been recognized in humans that Alzheimer's disease is a complex and polygenic disease, likely influenced by multiple variants, some with relatively small effect sizes (Lambert et al., 2013) . Here, we introduce the first genetically diverse population of AD mice -the AD-BXDs -as a useful model of human AD by demonstrating a high level of concordance between the AD-BXDs and human AD, both phenotypically and at the level of hippocampal transcriptome profiles. We further validated the AD-BXDs at the genetic level by identifying Apoe as a positional candidate located in a genomic interval significantly associated with cognitive deficits, and demonstrated the 'risk' allele in our population most closely matches the deleterious ε4 allele in humans. These results also validate CFC as a behavioral assay with predictive validity relative to human GWAS studies. Finally, using a combination of forward genetics and in vivo functional validation, we identify Trpc3 as a modulator of both age-related cognitive deficits and neuropathological accumulation of Aβ42 in AD. While multiple genes likely regulate cognitive function and Aβ42 accumulation in AD, the identification and validation of Trpc3 provides a novel therapeutic target and mechanistic pathway to be pursued in future studies.
Work presented here expands on several previous studies in mouse models that have attempted to identify precise genes involved in the modulation of AD pathology phenotypes (Ryman et al., 2008; Sebastiani et al., 2006) . However, in both cases, genetic intervals identified were too large to pinpoint causative variants. We utilized the BXD GRP for several reasons, including the fact that recombination intervals are much smaller than those observed in F2 populations, allowing for the identification of narrower QTLs than observed previously . Since each BXD line is fully inbred, each F1 AD-BXD line studied here can be reproduced across time and laboratories, maximizing the utility of our characterization of AD-BXD lines as either susceptible or resilient to AD. Our F1 strategy is also advantageous as it decreases the number of homozygous alleles in a panel and enhances hybrid vigor (Charlesworth and Willis, 2009 ).
Lastly, due to this reduction of homozygous alleles, allele-specific expression of a given gene can be monitored and quantified in a systematic way (Pandey and Williams, 2015) .
The role of modifier genes in normal aging and AD
The creation of the AD-BXD panel enables genetic mapping to identify true modifier alleles that influence the onset and severity of disease. However, interpretation of these modifiers in the context of normal aging is complex, as the extent to which genetic mechanisms underlying normal cognitive aging and AD overlap is still unclear. In principle, modifier alleles of interest could act in one of two ways: 1) as general modifier alleles that contribute to a phenotype regardless of disease status, or 2) specific AD modifiers that exhibit some type of epistatic relationship with the 5XFAD transgene and show no effect on phenotype in Ntg-BXD mice. Interestingly, we see examples of both instances in our results, suggesting both mechanisms are at play in our panel. For example, the peak marker in the QTL for CFM on chromosome 2 showed a significant association with CFM abilities in both AD-and Ntg-BXD mice (Figure 4D-E) .
However, in Ntg-BXD mice, this locus explained a smaller proportion of the variance (11%) compared to AD-BXD mice (21%) and would not have been detected by standard QTL mapping. Thus, the inclusion of the 5XFAD transgene as a sensitizer enabled the identification of a QTL that likely plays a small role in CFM abilities regardless of genotype, but which would have failed to be identified in studies of normal aging. Genes located in this interval likely represent broadly applicable therapeutic targets due to their role in both normal aging and AD. As an example of the second potential modifier mechanism, the QTL for CFC acquisition played no discernable role in regulating learning abilities in the Ntg-BXD population, suggesting this locus played a genotype-specific role and may act as an epistatic modifier of the 5XFAD transgene. These two examples highlight the particularly complex relationship between normal aging and Alzheimer's disease. It is also interesting to note that, as in humans, our identified QTLs do not explain all of the variation in their respective traits that are attributable to genetic factors. While this can be improved by increasing mapping power, our results and the lack of a QTL in AAO mapping further illustrates the point that multiple small effect variants with different roles (e.g additive, epistatic) in disease susceptibility contribute to a portion of the heritability of this complex disease.
Importance of genetic background in choosing a mouse model
Decades of research using AD mouse models have failed to translate into successful treatments for a variety of reasons, many of which have been discussed previously (Onos et al., 2016 ). Our results demonstrate that genetic variation profoundly affects the expressivity of the 5XFAD transgene on both cognitive and pathological traits. Thus, we conclude that a significant contributor to prior negative outcomes may be the lack of genetic diversity. Moreover, we demonstrate that the C57BL/6J genetic background harbors resilience factors that attenuate the impact of 5XFAD mutations on CFM (Figure 4B) , despite moderate-to-high levels of Aβ42 ( Figure 5B ). While this suggests the C57BL/6J mouse may be a valuable model in which to study resilience to AD-related neuropathologies, transgenic AD models created on the C57BL/6J background may pose problems for screening drug targets or understanding mechanisms that drive risk of AD.
Along with other genetically diverse models, the AD-BXD panel may provide new opportunities for preclinical screening that is directly beneficial to human patients. Since the 5XFAD transgene is not traditionally thought to induce significant tau pathology , we did not evaluate tau pathology in the AD-BXDs. However, naturally occurring variants in Mapt [see Sanger Mouse Genomes Project (Keane et al., 2011) ] segregate across our AD-BXD panel and may influence the production of hyperphosphorylated tau (and ultimately, neurofibrillary tangles). As tau and amyloid rarely occur together in mouse models, these strains (if identified) would both provide ideal models for preclinical screens in future studies and contribute to our understanding of the genetic variants modifying production and/or clearance of hyperphosphorylated tau. In addition, as tau has been seen to be more strongly associated with cognitive function in AD than other pathologies (Brier et al., 2016) , the AD-BXD panel may provide new opportunities to study the relationship between tau, amyloid, and cognitive function in the context of genetic diversity.
Trpc3 as a novel modulator of AD resilience
In order to contribute new understanding of mechanisms underlying resilience to disease, we pursued functional validation of Trpc3, an ion channel that had not previously been associated with AD, but for which we had strong biological evidence supporting a potential role in disease. Trpc3 is known to be permeable to calcium, and misregulation of calcium signaling is known to be one of the earliest events that occur in disease pathogenesis. Calcium regulation has also been shown to directly modulate Aβ production, thereby providing a mechanistic link between Trpc3 channels and Aβ42 modulation (LaFerla, 2002) . In addition, our lab has previously implicated Trpc3 as causally involved in the regulation of neuronal excitability and cognitive function, providing a biological link between Trpc3 channels and cognitive symptoms of AD . It was our hypothesis that targeting a gene that is both a known cognitive enhancer and putative mediator of Aβ42 levels would likely provide a double benefit to AD carriers by better allowing neurons to participate in networks critical for learning. Finally, a close family member of Trpc3, Trpc6, was recently shown to directly interact with amyloid precursor protein (APP), leading to a change in processing by gammasecretase and a reduction in overall Aβ levels (Wang et al., 2015) . Additional work is needed to determine whether Trpc3 mediates its effects on AD-related symptoms through regulation of calcium, neuronal excitability, or through a direct interaction with APP reminiscent of Trpc6. Regardless, the discovery that decreasing expression of Trpc3 in either normal aging or an aggressive mouse model of AD is sufficient to delay the onset of both cognitive and disease-specific pathological symptoms greatly contributes to our understanding of AD genetics, how they relate to mechanisms underlying normal aging, and provides an additional target on which to focus future studies.
One drawback of our current study is the lack of exhaustive functional testing of each positional candidate located in the QTL identified for Aβ42. It is likely that additional genes play a role, either independently or via an interaction with Trpc3, in determining severity of AD neuropathology. This idea is supported by the fact that positional candidates Fgf2
and Il2 have independently been associated with amyloid levels in model systems (Alves et al., 2017; Katsouri et al., 2015) . In addition, the QTL identified in our AD-BXD panel does not overlap with those broad regions associated with pathology previously (Ryman et al., 2008; Sebastiani et al., 2006) . While there are a variety of reasons why this may be the case, including the use of different experimental populations and quantitative traits, this phenomenon is likely best explained by the fact that AD is an incredibly complex disease (Rollo et al., 2016) , accompanied by complex endophenotypes such as Aβ42 accumulation, and is likely to be mediated by multiple genes with small effect sizes.
Therefore, continued expansion of the AD-BXD panel and/or related resources with even greater genetic diversity and power may enable discovery of many additional genes and mechanisms.
Conclusions and future directions
The ultimate goal of mouse studies relating to AD is the eventual translation of identified candidates into viable human therapeutics or biomarkers of disease. Our results suggest the AD-BXD panel is a valuable resource to do just that, as we demonstrate high levels of overlap between the AD-BXDs and human AD at the phenotypic, transcriptomic, and genetic level. In addition, we demonstrate genotype at Trpc3 is important for in mouse models determining resilience to AD, particularly AD neuropathology. In addition to utility as a potential biomarker, Trpc3 may be able to be targeted mechanistically to treat disease. The translational relevance of this idea is supported by the association identified here between levels of TRPC3 in human patients and a measure of brain-wide amyloid burden. Currently, selective antagonists for Trpc3 are commercially available (Kiyonaka et al., 2009 ), however they generally have poor bioavailability and contain potentially toxic moieties. Current work is aimed at adapting these antagonists to extend half-life and reduce the Genetic background modifies AD symptoms in a novel transgenic reference panel. A) Female C57BL/6J mice heterozygous for the 5XFAD transgene were bred to 26 BXD males to generate genetically diverse but isogenic F1 offspring. B) Body weight and working memory on the Y-maze was measured bi-monthly, and at 6 and 14 months more detailed phenotyping was carried out on a subset of mice. C) Onset of working memory deficits was significantly earlier in AD-BXDs compared to Ntg-BXD controls [as measured by average within-strain age at onset (AAO), AD-BXDs: n = 210 (109 females/101 males) across 24 strains vs Ntg-BXDs, n = 169 mice (106 female/63 male) across 25 strains, t(1,47) = 1.9, p = 0. Figure S1 and Tables S1-3.   0   2   4   6   8   10   12   14   16   18   14  89  99  22  60  16  42  81  55  61  69  62  65  75  68  87  44  70  66  51  32  77  100  56  D2  B6   0   1   2   3   4   5   Chromosome   LOD   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18 Figure S3 and Table S4 . Figure  S4 and Table S5 . Figure S5 and Table S6 . Figure 6: Knockdown of positional candidate Trpc3 delays AD symptoms in a mouse model of AD. A) TRPC3 protein is increased in the hippocampus of 5XFAD mice as measured by Western blot [n = 4/grp, t(1,6) = 3.74, p = 0.01]. B) AAV9 encoding either shRNA targeting Trpc3 (shRNA-Trpc3) or a scrambled control shRNA (shRNA-Ctrl) was delivered bilaterally into the hippocampus of presymptomatic 4 month-old 5XFAD mice. Working memory was assessed on the ymaze at 9m while CFM was assessed at 10m. C) There was a significant effect of group on working memory [F(2, 28) = 10.6, p < 0 
